Summary
Eighteen patients with advanced breast cancer were entered into a phase II study of fludarabine phosphate. Fludarabine phosphate was given by continuous infusion for 5 days, at a starting dose of 20 mg/m2 per day for patients previously treated with two or more regimens and 25 mg/m2 per day for minimally treated patients with less than two prior regimens; therapy was repeated every 3–4 weeks. Of the 18 patients, 11 had undergone more than two prior regimens and 7 patients had undergone one prior regimen. One patient achieved a partial response (PR) for 22 months. Myelosuppression was the most common toxicity observed. Four patients developed mild nausea and vomiting and two developed a nonspecific dermatitis that resolved spontaneously. No renal, hepato-, or neurotoxicity was observed. Our study demonstrates that in heavily pretreated patients, fludarabine phosphate given on this schedule has minimal efficacy in treating advanced breast cancer. This drug might possibly have shown more activity in a previously nontreated patient population. However, patients with advanced breast cancer, who have not undergone previous treatment are not often encountered.
Similar content being viewed by others
References
Brink JJ, Le Page GA (1964) Metabolic effects of 9-D-Arabinosylpurines in ascitic tumor cells. Cancer Res 24: 312
Brockman RW, Schable FM Jr, Montgomery JA (1977) Biologic activity of 9-β-D-arabino-fluranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabino-furanosyladenine. Biochem Pharmocol 26: 2193
Casper ES, Mittelman A, Kelsen D and Young CW (1985) Phase I clinical trial of fludarabine phosphate (F-ara-AMP). Cancer Chemother Pharmocol 15: 233
National Cancer Institute (1982) Fludarabine phosphate: data on file. National Cancer Institute, Bethesda, Md
Schabel FM Jr (1968) The anti-viral activity of 9-β-D-arabinofuranosyladenine (Ara-A) Chemotherapy 13: 321
Tseng WC, Derse D, Cheng YC, Brockman RW, Bennett LL (1981) “Self potentiation” mechanism of 9-β-D-arabinosylfuranosyl-2 fluoradenine. Fed Proc 40: 666
White L, Shaddix SC, Cheng YC, Brockman RW, Bennet jr. LL (1981) Inhibition of ribonucleotide reductase and DNA polymerase of tumor-cells by 9-β-D-arabinosyl-2-fluoroadenine-5′-triphosphate (2 F-ara-ATP) Proc Am Assoc Cancer Res 22: 33
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mittelman, A., Ashikari, R., Ahmed, T. et al. Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer. Cancer Chemother. Pharmacol. 22, 63–64 (1988). https://doi.org/10.1007/BF00254183
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254183